B Cell Depletion in Systemic Vasculitis

Smith, Riannon; Jayne, David

doi:10.2174/157339511797535108

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following the successful use of rituximab in rheumatoid arthritis and increasing appreciation of a role for B cells in the pathogenesis of AAV, several studies have reported responses to ritxumab for patients with relapsing or refractory disease [ 40 ]. The largest multicentre series of 65 patients with refractory disease reported complete remission in 75%, partial remission in 23%, and only one nonresponder.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Progress in treatment of ANCA-associated vasculitis

2012

View full text Add to dashboard Cite

Autoantibodies to neutrophil cytoplasmic antigen-associated vasculitis (AAV) is characterised by inflammation of blood vessels. The introduction of immunosuppressive therapy with glucocorticoids and cyclophosphamide transformed AAV from a fatal condition to a largely treatable condition. Over the past 30 years, considerable progress has been made refining immunosuppressive regimens with a focus on minimising toxicity. There is, however, a high unmet need in the treatment of AAV. A proportion of patients are refractory to current therapies; 50% experience a relapse within 5 years and treatment toxicity contributes to mortality and chronic disability. As knowledge of the pathogenesis of vasculitis grows, it is mirrored by the availability of biological agents, which herald a revolution in the treatment of vasculitis. Lymphocyte-targeted and cytokine-targeted agents have been evaluated for the treatment of AAV and are entering the routine therapeutic arena with the potential to improve patient outcomes. As rare diseases, treatment advances in vasculitis depend on international collaborative research networks both to establish an evidence base for newer agents and to develop recommendations for patient management.

show abstract

Section: Treatmentmentioning

confidence: 99%

“…Rituximab is now the preferred agent for refractory disease [ 41 ]. Rituximab was more effective than cyclophosphamide in the relapsing subgroup of the RAVE trial [ 40 ], although a retrospective series suggests it is less effective for granulomatous lesions, especially orbital masses than for vasculitic manifestations [ 60 ].…”

Section: Treatmentmentioning

confidence: 99%